AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

Impact of 2026 AHA/ACC Dyslipidemia Guidelines on Eligibility for Lipid Lowering Therapy in the United States

By Kalapura C, Bhatt DL, Mac Grory BC et al.

Background: The 2026 American Heart Association/American College of Cardiology (AHA/ACC) Dyslipidemia Guideline introduced new risk assessment strategies to define eligibility for lipid lowering therapy (LLT). The objective of this study is to determine the effect of these strategies on population-level eligibility for LLT in the United States. Methods: We used data from the 2021-2023 National Health and Nutrition Examination Survey (NHANES) to estimate the population eligible for lipid lowering therapy under 2026 AHA/ACC dyslipidemia guidelines compared with the 2018 AHA/ACC guidelines, which rely on the older pooled cohort risk equations (PCEs). Sampling weights were used to project NHANES sample characteristics to the United States population. Differences between the 2018 and 2026 guidelines, and our approach to implementing these criteria in NHANES data, are summarized in Figure 1. Results: A total of 2,904 NHANES participants had fasting laboratory data available and complete data for risk factors necessary to calculate therapy eligibility. Of these participants, 1,386 (37.0%) were eligible for LLT according to 2026 guidelines and 1,394 (37.4%) were eligible for LLT according to 2018 guidelines, corresponding to a weighted U.S. population of 89.6 million (95% CI 78.3 to 100.9 million) and 99.7 million (95% CI 87.5 to 111.9 million) respectively. On balance, there was no net change in the percentage of patients eligible for LLT (-0.3%, 95% CI -1.0% to 0.3%, p=0.38). Use of PREVENT equations versus PCEs decreased eligibility by 4.6%, which was counteracted by a 2.9% increase from changing the risk threshold from 7.5% to 5%, a 0.7% increase from including patients aged 30-39 and 76-79 in eligibility for PREVENT risk stratification, and a 0.7% increase from making CKD an eligibility criterion for LLT. CVD risk estimates and LLT eligibility thresholds are shown in Figure 2 . Differences in therapy eligibility by subgroup are shown in Figure 3, highlighting increased eligibility among female patients (+0.7%, 95% CI +0.2 to 1.3%) and patients aged 70-79 (+6.5%, 95% CI +4.1-9.0%) and decreased eligibility among male patients (-1.4%, 95% CI -2.3 to -0.5%) and patients aged 60-69 (-4.3%, 95% CI -5.9% to -2.8%). Conclusions: While updated recommendations from the 2026 AHA/ACC Guidelines result in no net change in LLT eligibility in the United States, differences across subgroups are substantial, especially among women and those older than 70 years.

doi.org/10.1161/circ.154.suppl_1.8954Industry & policy

AgingResearch.News